Replidyne starts phase 1 study of topical anti-infective drug REP8839

By Lisa Kerner

Charlotte, N.C., July 18 - Replidyne, Inc. said it began phase 1 clinical testing of its topical anti-infective drug candidate REP8839 for treatment of skin and wound infections and the prevention of S. aureus infections including methicillin resistant S. aureus (MRSA) infections in hospital settings.

In the study of 110 healthy adults, various concentrations of REP8839 will be studied alone and in combination with the topical antibiotic mupirocin.

The clinical endpoint of the trial is an evaluation of intact and abraded skin following daily dosing of REP8839 alone and in combination with mupirocin, at two, 14 and 21 days.

Additional phase 1 trials are planned to assess the pharmacokinetics and sensitization to re-treatment.

REP8839 inhibits the enzyme methionyl tRNA synthetase, resulting in attenuation of bacterial growth.

Located in Louisville, Colo., Replidyne is a biopharmaceutical company discovering, developing, in-licensing and commercializing anti-infective products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.